Home Stock

Stock Research: ANI Pharma

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

ANI Pharma

NMQ:ANIP US00182C1036
96
  • Value
    58
  • Growth
    90
  • Safety
    Safety
    80
  • Combined
    98
  • Sentiment
    59
  • 360° View
    360° View
    96
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes therapeutics. It operates in the biopharmaceutical industry, with a focus on rare disease conditions and branded pharmaceutical products. The company's operations are primarily within the United States. In the last fiscal year, the company had a market cap of $1,379 million, profits of $364 million, and revenue of $614 million, with 897 employees.

more

ANALYSIS: With an Obermatt 360° View of 96 (better than 96% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock ANI Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all four indicators above average for ANI Pharma. The consolidated Value Rank has an attractive rank of 58, which means that the share price of ANI Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 58% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 90, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The company is also safely financed with a Safety rank of 80. Finally, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 59. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Pro Holdings
Country USA
Industry Pharmaceuticals
Size Medium
Website anipharmaceuticals.com
Index
NASDAQ
ANI Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
58 53 42 61
Growth
90 59 79 85
Safety
Safety
80 69 55 36
Sentiment
59 80 96 34
360° View
360° View
96 88 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
36 83 76 17
Opinions Change
50 50 83 92
Pro Holdings
n/a 36 74 49
Market Pulse
30 91 48 30
Sentiment
59 80 96 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
58 53 42 61
Growth
90 59 79 85
Safety Safety
80 69 55 36
Combined
98 76 73 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
82 55 44 56
Price vs. Earnings (P/E)
29 70 68 87
Price vs. Book (P/B)
55 42 39 46
Dividend Yield
1 1 1 1
Value
58 53 42 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
88 83 41 77
Profit Growth
86 53 98 35
Capital Growth
37 30 37 59
Stock Returns
44 49 77 91
Growth
90 59 79 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
23 47 38 40
Refinancing
96 63 77 41
Liquidity
67 57 40 44
Safety Safety
80 69 55 36

Similar Stocks

Discover high‑ranked alternatives to ANI Pharma and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Phibro Animal Health

NMQ:PAHC
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

FedEx

NYQ:FDX
Country: USA
Industry: Air Freight & Logistics
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

This is an all-around strong stock. It shows good value, high growth, safe financing, and positive professional sentiment. It is ideal for most buy-and-hold investors who value a good all-around stock.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews